Published online before print May 9, 2005, doi: 10.1161/01.HYP.0000166141.69081.80
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Hypertension. 2005;45:1131.)
© 2005 American Heart Association, Inc.
Original Articles |
Cyclooxygenase-1–Deficient Mice Have High Sleep-to-Wake Blood Pressure Ratios and Renal Vasoconstriction
From the Cardiovascular Kidney Institute and Division of Nephrology and Hypertension (N.K., G.S., N.I., S.C., K.D., P.M., R.H., J.T.K., W.J.W., C.S.W.), Georgetown University, Washington, DC; the Division of Nephrology (E.I.), Osaka University Graduate School of Medicine, Osaka, Japan; and the Comparative Medicine Branch (R.L.), National Institutes of Health, National Institute of Environmental Health Sciences, Research Triangle Park, NC.
Correspondence to Dr Christopher S. Wilcox, Division of Nephrology and Hypertension, Georgetown University Medical Center, 3800 Reservoir Road, NW, PHCF6003, Washington, DC 20007-2197. E-mail wilcoxch{at}georgetown.edu
 |
Abstract |
|---|
 Top Abstract IntroductionMethodsResultsDiscussionReferences |
|---|
We used cyclooxygenase-1 (COX-1)–deficient mice to test the hypothesis that COX-1 regulates blood pressure (BP) and renal hemodynamics. The awake time (AT) mean arterial pressures (MAPs) measured by telemetry were not different between COX-1+/+ and COX-1–/– (131±2 versus 126±3 mm Hg; NS). However, COX-1–/– had higher sleep time (ST) MAP (93±1 versus 97±2 mm Hg; P<0.05) and sleep-to-awake BP ratio (+8.6%; P<0.05). Under anesthesia with moderate sodium loading, COX-1–/– had higher MAP (109±5 versus 124±4 mm Hg; P<0.05), renal vascular resistance (23.5±1.6 versus 30.7±1.7 mm Hg · mL–1 · min–1 · g–1; P<0.05) and filtration fraction (33.7±2.1 versus 40.2±2.0%; P<0.05). COX-1–/– had a 89% reduction (P<0.0001) in the excretion of TxB2, a 76% reduction (P<0.01) in PGE2, a 40% reduction (P<0.0002) in 6-ketoPGF1
(6keto), a 27% reduction (P<0.02) in 11-ßPGF2 (11ß), a 35% reduction (P<0.01) in nitrate plus nitrite (NOx), and a 52% increase in metanephrine (P<0.02). The excretion of normetanephrine, a marker for sympathetic nervous activity, was reduced during ST in COX-1+/+ (6.9±0.9 versus 3.2±0.6 g · g–1 creatinine · 10–3; P<0.01). This was blunted in COX-1–/– (5.1±0.9 versus 4.9±0.7 g · g–1 creatinine · 10–3; NS). Urine collection during ST showed lower excretion of 6keto, 11ß, NOx, aldosterone, sodium, and potassium than during AT in both COX-1+/+ and COX-1–/–, and there were positive correlations among these parameters (6keto versus NOx; P<0.005; 11ß versus NOx; P<0.005; and NOx versus sodium; P<0.005). In conclusion, COX-1 mediates a suppressed sympathetic nervous activity and enhanced NO, which may contribute to renal vasodilatation and a reduced MAP while asleep or under anesthesia. COX-1 contributes to the normal nocturnal BP dipping phenomenon.
Key Words: hypertension • nitric oxide • prostaglandins • renal circulation • sympathetic nervous activity
|
Introduction |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Cyclooxygenase (COX) converts arachidonate to prostaglandin (PG) H2 (PGH2),1,2 which can activate thromboxane-PGH2 receptors. However, in vivo, PGH2 is promptly metabolized to several biological active PGs and thromboxane A2 (TxA2). COX produces both vasoconstrictor and vasodilatator metabolites. Therefore, its role in the regulation of BP and hemodynamics is difficult to predict and may explain the positive and negative studies regarding the effect of nonselective COX inhibitors (nonsteroidal anti-inflammatory drugs [NSAIDs]) on blood pressure (BP) in human. However, a metaanalysis showed a 5.0-mm Hg increase in the BP in NSAID users.3
COX-2 is inducible,4–6 but in the kidney it is expressed constitutively in vascular endothelial cells, afferent arterioles, cortical thick ascending limbs, macula densa cells, and glomeruli.7,8 COX-2 regulates renin secretion.7 COX-1 is expressed in the extraglomerular and intraglomerular mesangium, the terminal distal convoluted tubule, collecting duct, and vascular endothelial cells.9,10 Previous studies by Athirakul et al11 have shown that COX-1 gene–deficient (COX-1–/–) mice fail to conserve salt, leading to an exaggerated decline in the mean arterial pressure (MAP) during salt restriction. They also have diminished pressor and renal vasoconstrictor responses during an acute infusion of angiotensin II.12 These studies suggest that COX-1 may be required to maintain BP during states of high angiotensin II. However, less is known concerning the role of COX-1 during states of normal or low angiotensin II. This study was conducted in mice consuming a normal salt diet.
A loss of the normal reduction in BP during sleep ("nondipping" status) increases the risk for cardiovascular disease,13–16 but the mechanism is not clear. The decline in nocturnal BP is associated with a reduced sympathetic nervous system tone.17 Loss of the nocturnal decline in BP is accompanied by reduced physical activity,18 increased NaCl reabsorption,19,20 and impaired endothelial function.13 Because COX-1 may regulate NaCl reabsorption and endothelial function, we assessed the sleep-to-awake BP pattern in these mice using telemetry to test the hypothesis that COX-1 products mediate the normal circadian fluctuation in BP.
The first aim of this study was to determine the role of COX-1 in the regulation of BP and renal hemodynamics. The MAP was measured by telemetry in unanesthetized mice and by intra-arterial recording under anesthesia during clearance studies in COX-1 gene–deficient (COX-1–/–) and wild (COX-1+/+) mice. The second aim of this study was to evaluate the role of COX-1 on the circadian regulation of several bioactive markers. Mice urine samples were collected separately during day and night. The renal excretion of sodium, potassium, metanephrine, normetanephrine, aldosterone, nitrate plus nitrite (NOx), and prostaglandins or their metabolites (TxB2, 6-ketoPGF1, PGE2, and 11-ßPGF2) were measured to assess their potential roles in the functional changes observed.
|
Methods |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Animals
The generation and genotyping of COX-1 gene–deficient mice (Black6/129 background) have been reported.21 Male homozygous (COX-1–/–) and wild (COX-1+/+) mice were housed in a quiet room at 25°C with a 12-hour light/dark cycle with free access to food and water. This study was approved by the Georgetown University Animal Care and Use Committee.
Telemetry
The surgical procedure to implant telemetry is detailed in the online data supplement (available at http://www.hypertensionaha.org). The hourly BP, heart rate (HR), and physical activity data were collected, and the mean and standard error of the mean (SEM) values for groups of mice in synchronized time were calculated and plotted as shown in Figure 1. The mean of the lowest 4 sets of MAPs, HRs, and physical activities during the 6:00 AM to 6:00 PM (day time) within the same day (sleep period) and the highest 4 sets of MAPs, HRs, and physical activities during the next 6:00 PM to 6:00 AM (nighttime: awake time period) were calculated in individual COX-1+/+ (n=10) and COX-1–/– mice (n=9).
|
Renal Function Studies
The protocol of the renal function study is detailed in the online data supplement.
Renal Excretion of Sodium, Potassium, TxB2, 6-ketoPGF1, PGE2, 11-ßPGF2, Nephrines, and NOx
Mice (n=6 each group) were housed in mouse metabolic cages (Nalgene Nunc International, Rochester, NY) with NOx-free synthetic diet (Na+ content 0.4 g · 100 g–1). Urine was collected from 6:00 AM to 6:00 PM for sleep (daytime) sample and the next 6:00 PM to 6:00 AM for awake (nighttime) sample. Measurement of each parameter is detailed in the online data supplement.
Chemical Methods and Statistics
Chemical methods were those published previously.22 Statistics are detailed in the online data supplement.
|
Results |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Hematocrit, Total Body and Kidney Weights, Plasma Electrolytes, and Urinary Volume of COX-1–/– and COX-1+/+ Mice
There were no differences in these parameters between COX-1+/+ and COX-1–/– mice (supplemental Table I, available online at http://www.hypertensionaha.org).
MAP, HR, and Physical Activity Measured by Telemetry
Figure 1 shows the hourly mean±SEM values of MAP (Figure 1A), HR (Figure 1B), and physical activity (supplemental Figure I) in groups of COX-1–/– and COX-1+/+ mice measured by telemetry for 5 days. In both groups, MAP, HR, and activity were elevated at night (awake) and reduced during the day (sleep). Figure 2 shows the calculated sleep and awake MAPs (Figure 2A) and sleep-to-awake BP ratios (Figure 2B). Although there was no significant difference in awake MAP (COX-1+/+: 131±2 mm Hg; COX-1–/–: 126±3 mm Hg), the sleep MAP (COX-1+/+: 93±1 mm Hg; COX-1–/–: 97±2 mm Hg) and the sleep-to-awake BP ratio was higher in COX-1–/– mice by 8.6%. This was accompanied by a 5.7% increase in sleep-to-awake HR ratio (Figure 3), but there were no differences in physical activity (supplemental Figure II).
|
|
MAP and HR Under Anesthesia
When measured by direct intra-arterial catheterization under anesthesia with moderate salt loading, the MAP of COX-1–/– mice (124±4 mm Hg) was higher than COX-1+/+ mice (109±5 mm Hg), but there was no difference in HR (supplemental Figure III).
Renal Function Under Anesthesia
The glomerular filtration rate was not different (COX-1+/+: 0.89±0.06 mL · min–1 · g–1; COX-1–/–: 0.93±0.04 mL · min–1 · g–1), but COX-1–/– mice had a reduced renal blood flow (RBF) (COX-1+/+: 4.7±0.2 mL · min–1 · g–1; COX-1–/–: 4.1±0.2 mL · min–1 · g–1; supplemental Figure IVA and IVB) and increased filtration fraction (FF) (COX-1+/+: 34±2%; COX-1–/–: 40±2%) and renal vascular resistance (RVR) (COX-1+/+: 24±2 mm Hg · mL–1 · min–1 · g–1; COX-1–/–: 31±2 mm Hg · mL–1 · min–1 · g–1; supplemental Figure IVC and IVD).
Renal Excretion of Sodium and Potassium
The excretion of sodium and potassium was reduced during sleep (supplemental Figure V). COX-1 did not affect excretion of sodium or potassium.
Renal Excretion of TxB2, PGE2, 6-ketoPGF1, and 11-ßPGF2
The renal excretion of TxB2 in the COX-1+/+ awake, COX-1–/– awake, COX-1+/+ sleep, and COX-1–/– sleep groups are 4.0±0.2, 0.4±0.1, 3.8±0.3, and 0.4±0.1 g · g–1 creatinine · 10–6, respectively. The renal excretion of PGE2 in the COX-1+/+ awake, COX-1–/– awake, COX-1+/+ sleep, and COX-1–/– sleep groups are 1.9±0.4, 0.4±0.1, 1.4±0.6, and 0.4±0.1 g · g–1 creatinine · 10–6, respectively. The renal excretion of 6-ketoPGF1 in the COX-1+/+ awake, COX-1–/– awake, COX-1+/+ sleep, and COX-1–/– sleep groups are 1.6±0.1, 1.0±0.1, 1.3±0.1, and 0.8±0.1 g · g–1 creatinine · 10–6, respectively. The renal excretion of 11-ßPGF2 in the COX-1+/+ awake, COX-1–/– awake, COX-1+/+ sleep, and COX-1–/– sleep groups are 0.090±0.009, 0.062±0.004, 0.064±0.005, and 0.050±0.003 g · g–1 creatinine · 10–6, respectively. COX-1–/– had a 89% reduction in the excretion of TxB2, a 76% reduction in PGE2, a 40% reduction in 6-ketoPGF1, and a 27% reduction in 11-ßPGF2. Excretion of 6-ketoPGF1 and 11-ßPGF2 were reduced during sleep, but TxB2 or PGE2 were not changed (Figure 4).
|
Renal Excretion of Catecholamine Metabolites
The renal excretion of metanephrine in the COX-1+/+ awake, COX-1–/– awake, COX-1+/+ sleep, and COX-1–/– sleep groups are 0.037±0.005, 0.049±0.004, 0.032±0.004, and 0.056±0.007 g · g–1 creatinine · 10–3, respectively. The renal excretion of normetanephrine in the COX-1+/+ awake, COX-1–/– awake, COX-1+/+ sleep, and COX-1–/– sleep groups are 6.9±0.9, 5.1±0.9, 3.2±0.6, and 4.9±0.7 g · g–1 creatinine · 10–3, respectively. Excretion of metanephrine was not different during awake time and sleep time but was increased in COX-1–/– mice. Excretion of normetanephrine was reduced during sleep time. COX-1–/– mice had a higher normetanephrine excretion only during the sleep time (Figure 5A and 5B).
|
Renal Excretion of NOx and Aldosterone
The renal excretion of NOx in the COX-1+/+ awake, COX-1–/– awake, COX-1+/+ sleep, and COX-1–/– sleep groups are 0.33±0.06, 0.22±0.04, 0.19±0.03, and 0.12±0.02 mol · mol–1 creatinine · 10–6, respectively. The renal excretion of aldosterone in the COX-1+/+ awake, COX-1–/– awake, COX-1+/+ sleep, and COX-1–/– sleep groups are 0.017±0.002, 0.017±0.003, 0.012±0.001, and 0.010±0.002 g · g–1 creatinine · 10–3, respectively. Excretion of NOx and aldosterone were reduced during sleep time. COX-1–/– mice had reduced excretion of NOx but not aldosterone (Figure 5C and 5D).
Correlation Analysis Among Tx/PGs Metabolites and NOx
Renal excretion of NOx was positively correlate with excretion of 6-ketoPGF1 and 11-ßPGF2 (Figure 6A and 6B), but not with TxB2 or PGE2 (supplemental Figure VI).
|
Correlation Analysis Between Sodium and NOx
Renal excretion of sodium was positively correlated with NOx (Figure 6C).
|
Discussion |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
A novel finding is that COX-1–/– mice have higher sleep time MAP and increased ratios of sleep:awake BP and HR. The importance of circadian rhythm in BP was recognized by O’Brien et al who introduced the "dipper/nondipper" classification and showed that nondipper status is a risk factor for stroke.14 Staessen et al and Okubo et al15,16 showed further that a 5% increment in the night-to-day BP ratio is associated with a 20% increase in cardiovascular events or death even in normotensive subjects. The normal decrement in night-to-day BP in humans has been related to nocturnal reductions in physical activity18 and sympathetic nervous system tone.17 However, increased NaCl reabsorption19,20 or endothelial dysfunction13 impair the normal night-to-day BP ratio. We found that COX-1 deficiency does not change physical activity, but increases sleep:awake HR ratio. Because HR is regulated by the sympathetic nervous system, a blunting of the nocturnal reduction in the sympathetic nervous system tone could be a cause for the higher sleep:awake BP and HR ratios in COX-1–/– mice. We measured normetanephrine excretion to index sympathetic nervous system activity. The result confirmed that normetanephrine excretion in wild-type mice declines by 60% while the animals are asleep. In contrast, there were no circadian changes in COX-1–/– mice (Figure 5B) (interaction day–nightxCOX-1; P<0.01). Consequently, COX-1–/–, relative to COX-1+/+ mice, have an increased normetanephrine excretion while asleep, consistent with increased sympathetic nervous system tone. COX-1–/– mice also had increased excretion of metanephrine, suggesting increased epinephrine secretion. The excretion of NOx or aldosterone failed to explain the higher sleep:awake BP ratio in COX-1–/– mice (Figure 5C and 5D) (interaction day–nightxCOX-1; not significant).
Presently, the cause of the enhanced sympathetic nervous system activity during sleep time in COX-1–/– mice is not clear. PGE2 can activate sympathetic nerves in kidney23 and in central nervous system (paraventricular nucleus of hypothalamus),24 and PGD2 can activate norepinephric neurons in the hypothalamus.25 Whether local COX-1–dependent PGE2/D2 production in the brain or peripheral nerves underlies the circadian rhythm of sympathetic nervous system activity requires further study.
COX-1–/– mice had an increased MAP when studied under anesthesia with moderate saltwater loading (1.5% albumin in saline at a rate of 0.35 mL/h) accompanied by an increased RVR and FF and a decreased RBF. This renal vasoconstriction may have contributed to the increased BP. Because anesthetic drugs blunt the action of catecholamines, the cause of the renal vasoconstriction in COX-1–/– mice under anesthesia is not likely to be attributed to an increase in catecholamines and sympathetic nervous activity. It also cannot be attributed to an increased ratio of vasoconstrictor TxA2 to vasodilatator PGs, because COX-1–/– mice had a more marked reduction in renal excretion of TxB2 than 6-ketoPGF1, consistent with previous studies that TxA2 is mainly generated by COX-1, whereas both COX-1 and COX-2 contribute to the production of PGI2.26 There was no difference in excretion of aldosterone between COX-1–/– and COX-1+/+ mice.
Our finding that COX-1–/– mice have a reduced excretion of NO metabolites suggests that the cause for the renal vasoconstriction seen in COX-1–/– mice may rather relate to defective generation of NO. Similar to our finding in COX-1–/– mice, NSAIDs reduce NO production.27,28 We found a strong positive correlation between the renal excretion of sodium and NOx. Inhibition of NO generation with L-nitro methyl arginine ester causes salt-sensitivity, accompanied by reduced renal Na+ excretion and renal vasoconstriction with an elevated FF and hypertension.29–33 These are all features of the COX-1–/– mouse in this study. Therefore, a reduction in NO generation may underlie the hemodynamic change seen in COX-1–/– mice.
The role of PGs in NO production needs further study. We found strong correlations between the renal excretion of NOx with PGI2 and PGD2 metabolites, but not with TxA2 or PGE2 metabolites. Zenge34 has shown PGI2-induced pulmonary vasodilatation is mediated by NO release. Niwano35 has shown that the PGI2 analogue, Beraprost sodium, increases endothelial nitric oxide synthase gene expression and releases NO from endothelial cells via cAMP signaling. PGD2 increases endothelial nitric oxide synthase expression and NO generation in the developing choroids.36 The PGD2 metabolite, 15-deoxy-delta12,14-PG J2 (15d-PGJ2), also increases NO generation by endothelial cells,37 but the molecular mechanism is not yet established.
Perspectives
NSAIDs can cause renal vasoconstriction and raise BP in patients with hypertension. The similar profile of effects of COX-1 gene deletion in this study to that of NSAIDs recipients suggest that some of the adverse effects associated with NSAIDs use may originate from inhibition of COX-1. Likely, these potential adverse cardiovascular effects are offset by inhibition of platelet COX-1 that will inhibit thrombogenesis. The profound reduction in NOx excretion and increased nocturnal excretion of normetanephrine in COX-1–/– mice implies a new role for this enzyme, and likely its products, PGI2 and PGD2 or their metabolites in NO generation and sympathetic drive. Defects in NO generation are linked to atherosclerosis and adverse cardiovascular outcome in many clinical studies. These findings expose complex, and perhaps discordant, effects of COX-1 metabolites on potential cardiovascular risk factors that add to the growing concern of unanticipated cardiovascular events in patients using drugs that inhibit cyclooxygenase.
|
Acknowledgments |
|---|
This work was supported by grants from the National Institute of Diabetes, Digestive, and Kidney Disease (DK-36,079 and DK-49,870), the National Heart, Lung, and Blood Institute (HL-68686), and American Heart Association Beginning grant-in-aid (PI: N Kawada; 0465440U), and by funds from the George E Schreiner Chair of Nephrology.
Received November 22, 2004; first decision December 16, 2004; accepted April 2, 2005.
|
References |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
1. DeWitt DL, Smith WL. Primary structure of prostaglandin G/H synthase from sheep vesicular gland determined from the complementary DNA sequence. Proc Natl Acad Sci U S A. 1988; 85: 1412–1416.
2. Smith WL, Dewitt DL. Prostaglandin endoperoxide H synthases-1 and -2. Adv Immunol. 1996; 62: 167–215.[Medline] [Order article via Infotrieve]
3. Johnson AG, Nguyen TV, Day RO. nonsteroidal anti-inflammatory drugs affect blood pressure? A meta-analysis. Ann Intern Med. 1994; 121: 289–300.
4. Sheng H, Shao J, Morrow JD, Beauchamp RD, DuBois RN. Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells. Cancer Res. 1998; 58: 362–366.
5. Ishaque A, Dunn MJ, Sorokin A. Cyclooxygenase-2 inhibits tumor necrosis factor alpha-mediated apoptosis in renal glomerular mesangial cells. J Biol Chem. 2003; 278: 10629–10640.
6. Cutler NS, Graves-Deal R, LaFleur BJ, Gao Z, Boman BM, Whitehead RH, Terry E, Morrow JD, Coffey RJ. Stromal production of prostacyclin confers an antiapoptotic effect to colonic epithelial cells. Cancer Res. 2003; 63: 1748–1751.
7. Harris RC, McKanna JA, Akai Y, Jacobson HR, Dubois RN, Breyer MD. Cyclooxygenase-2 is associated with the macula densa of rat kidney and increases with salt restriction. J Clin Invest. 1994; 94: 2504–2510.[Medline] [Order article via Infotrieve]
8. Harris RC, Breyer MD. Physiological regulation of cyclooxygenase-2 in the kidney. Am J Physiol. 2001; 281: F1–F11.
9. Smith WL, Bell TG. Immunohistochemical localization of the prostaglandin-forming cyclooxygenase in renal cortex. Am J Physiol. 1978; 235: F451–F457.[Medline] [Order article via Infotrieve]
10. Campean V, Theilig F, Paliege A, Breyer M, Bachmann S. Key enzymes for renal prostaglandin synthesis: site-specific expression in rodent kidney (rat, mouse). Am J Physiol. 2003; 285: F19–F32.
11. Athirakul K, Kim HS, Audoly LP, Smithies O, Coffman TM. Deficiency of COX-1 causes natriuresis and enhanced sensitivity to ACE inhibition. Kidney Int. 2001; 60: 2324–2329.[CrossRef][Medline] [Order article via Infotrieve]
12. Qi Z, Hao CM, Langenbach RI, Breyer RM, Redha R, Morrow JD, Breyer MD. Opposite effects of cyclooxygenase-1 and -2 activity on the pressor response to angiotensin II. J Clin Invest. 2002; 110: 61–69.[CrossRef][Medline] [Order article via Infotrieve]
13. Shaw JA, Chin-Dusting JP, Kingwell BA, Dart AM. Diurnal variation in endothelium-dependent vasodilatation is not apparent in coronary artery disease. Circulation. 2001; 103: 806–812.
14. O’Brien E, Sheridan J, O’Malley K. Dippers and non-dippers. Lancet. 1988; 2: 397.[Medline] [Order article via Infotrieve]
15. Staessen JA, Thijs L, Fagard R, O’Brien ET, Clement D, de Leeuw PW, Mancia G, Nachev C, Palatini P, Parati G, Tuomilehto J, Webster J. Predicting cardiovascular risk using conventional vs ambulatory blood pressure in older patients with systolic hypertension. Systolic Hypertension in Europe Trial Investigators. JAMA. 1999; 282: 539–546.
16. Ohkubo T, Hozawa A, Yamaguchi J, Kikuya M, Ohmori K, Michimata M, Matsubara M, Hashimoto J, Hoshi H, Araki T, Tsuji I, Satoh H, Hisamichi S, Imai Y. Prognostic significance of the nocturnal decline in blood pressure in individuals with and without high 24-h blood pressure: the Ohasama study. J Hypertens. 2002; 20: 2183–2189.[CrossRef][Medline] [Order article via Infotrieve]
17. Dodt C, Breckling U, Derad I, Fehm HL, Born J. Plasma epinephrine and norepinephrine concentrations of healthy humans associated with nighttime sleep and morning arousal. Hypertension. 1997; 30: 71–76.
18. O’Shea JC, Murphy MB. Nocturnal blood pressure dipping: a consequence of diurnal physical activity blipping? Am J Hypertens. 2000; 13: 601–606.[CrossRef][Medline] [Order article via Infotrieve]
19. Staessen JA, Birkenhager W, Bulpitt CJ, Fagard R, Fletcher AE, Lijnen P, Thijs L, Amery A. The relationship between blood pressure and sodium and potassium excretion during the day and at night. J Hypertens. 1993; 11: 443–447.[Medline] [Order article via Infotrieve]
20. Uzu T, Ishikawa K, Fujii T, Nakamura S, Inenaga T, Kimura G. Sodium restriction shifts circadian rhythm of blood pressure from nondipper to dipper in essential hypertension. Circulation. 1997; 96: 1859–1862.
21. Langenbach R, Morham SG, Tiano HF, Loftin CD, Ghanayem BI, Chulada PC, Mahler JF, Lee CA, Goulding EH, Kluckman KD, Kim HS, Smithies O. Prostaglandin synthase 1 gene disruption in mice reduces arachidonic acid-induced inflammation and indomethacin-induced gastric ulceration. Cell. 1995; 83: 483–492.[CrossRef][Medline] [Order article via Infotrieve]
22. Kawada N, Imai E, Karber A, Welch WJ, Wilcox CS. A mouse model of angiotensin II slow pressor response: role of oxidative stress. J Am Soc Nephrol. 2002; 13: 2860–2868.
23. MacNeil BJ, Jansen AH, Greenberg AH, Nance DM. Neuropeptide specificity of prostaglandin E2-induced activation of splenic and renal sympathetic nerves in the rat. Brain Behav Immun. 2003; 17: 442–452.[Medline] [Order article via Infotrieve]
24. Zhang ZH, Wei SG, Francis J, Felder RB. Cardiovascular and renal sympathetic activation by blood-borne TNF-alpha in rat: the role of central prostaglandins. Am J Physiol. 2003; 284: R916–R927.
25. Terao A, Kitamura H, Asano A, Kobayashi M, Saito M. Roles of prostaglandins D2 and E2 in interleukin-1-induced activation of norepinephrine turnover in the brain and peripheral organs of rats. J Neurochem. 1995; 65: 2742–2747.[Medline] [Order article via Infotrieve]
26. Belton O, Byrne D, Kearney D, Leahy A, Fitzgerald DJ. Cyclooxygenase-1 and -2-dependent prostacyclin formation in patients with atherosclerosis. Circulation. 2000; 102: 840–845.
27. Amin AR, Attur MG, Pillinger M, Abramson SB. The pleiotropic functions of aspirin: mechanisms of action. Cell Mol Life Sci. 1999; 56: 305–312.[CrossRef][Medline] [Order article via Infotrieve]
28. Ryu YS, Lee JH, Seok JH, Hong JH, Lee YS, Lim JH, Kim YM, Hur GM. Acetaminophen inhibits iNOS gene expression in RAW 264.7 macrophages: differential regulation of NF-kappaB by acetaminophen and salicylates. Biochem Biophys Res Commun. 2000; 272: 758–764.[CrossRef][Medline] [Order article via Infotrieve]
29. Baylis C, Mitruka B, Deng A. Chronic blockade of nitric oxide synthesis in the rat produces systemic hypertension and glomerular damage. J Clin Invest. 1992; 90: 278–281.[Medline] [Order article via Infotrieve]
30. Ribeiro MO, Antunes E, de Nucci G, Lovisolo SM, Zatz R. Chronic inhibition of nitric oxide synthesis. A new model of arterial hypertension. Hypertension. 1992; 20: 298–303.
31. Rodriguez-Perez JC, Brenner BM. Renal effects of an acute NaCl load in chronic nitric oxide blockade-induced hypertensive rats. J Physiol Biochem. 1998; 54: 127–133.[Medline] [Order article via Infotrieve]
32. Krukoff TL. Central actions of nitric oxide in regulation of autonomic functions. Brain Res Brain Res Rev. 1999; 30: 52–65.[Medline] [Order article via Infotrieve]
33. Zanzinger J. Role of nitric oxide in the neural control of cardiovascular function. Cardiovasc Res. 2000; 43: 639–649.
34. Zenge JP, Rairigh RL, Grover TR, Storme L, Parker TA, Kinsella JP, Abman SH. NO and prostaglandin interactions during hemodynamic stress in the fetal ovine pulmonary circulation. Am J Physiol. 2001; 281: L1157–L1163.
35. Niwano K, Arai M, Tomaru K, Uchiyama T, Ohyama Y, Kurabayashi M. Transcriptional stimulation of the eNOS gene by the stable prostacyclin analogue beraprost is mediated through cAMP-responsive element in vascular endothelial cells: close link between PGI2 signal and NO pathways. Circ Res. 2003; 93: 523–530.
36. Dumont I, Hardy P, Peri KG, Hou X, Molotchnikoff S, Varma DR, Chemtob S. Regulation of endothelial nitric oxide synthase by PGD2 in the developing choroids. Am J Physiol. 2000; 278: H60–H66.
37. Calnek DS, Mazzella L, Roser S, Roman J, Hart CM. Peroxisome proliferator-activated receptor gamma ligands increase release of nitric oxide from endothelial cells. Arterioscler Thromb Vasc Biol. 2003; 23: 52–57.
This article has been cited by other articles:
 |
|
 |
|
  S. M. Kim, Y. Huang, Y. Qin, D. Mizel, J. Schnermann, and J. P. Briggs Persistence of circadian variation in arterial blood pressure in {beta}1/{beta}2-adrenergic receptor-deficient mice Am J Physiol Regulatory Integrative Comp Physiol, May 1, 2008; 294(5): R1427 - R1434. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. J. Welch, K. Patel, P. Modlinger, M. Mendonca, N. Kawada, K. Dennehy, S. Aslam, and C. S. Wilcox Roles of vasoconstrictor prostaglandins, COX-1 and -2, and AT1, AT2, and TP receptors in a rat model of early 2K,1C hypertension Am J Physiol Heart Circ Physiol, November 1, 2007; 293(5): H2644 - H2649. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Yu, J. Fan, Y. Hui, C. A. Rouzer, L. J. Marnett, A. J. Klein-Szanto, G. A. FitzGerald, and C. D. Funk Targeted Cyclooxygenase Gene (Ptgs) Exchange Reveals Discriminant Isoform Functionality J. Biol. Chem., January 12, 2007; 282(2): 1498 - 1506. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Ye, H. Zhang, E. Hillas, D. E. Kohan, R. L. Miller, R. D. Nelson, M. Honeggar, and T. Yang Expression and function of COX isoforms in renal medulla: evidence for regulation of salt sensitivity and blood pressure Am J Physiol Renal Physiol, February 1, 2006; 290(2): F542 - F549. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. Bek, X. Wang, L. D. Asico, J. E. Jones, S. Zheng, X. Li, G. M. Eisner, D. K. Grandy, R. M. Carey, P. Soares-da-Silva, et al. Angiotensin-II Type 1 Receptor-Mediated Hypertension in D4 Dopamine Receptor-Deficient Mice Hypertension, February 1, 2006; 47(2): 288 - 295. [Abstract] [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||